Drug Type VHH-Fc |
Synonyms rimteravimab, XVR-011 |
Target |
Action inhibitors |
Mechanism SARS-CoV-2 S protein inhibitors(SARS-CoV-2 S protein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Start Date26 Aug 2021 |
Sponsor / Collaborator |
Start Date05 Aug 2021 |
Sponsor / Collaborator |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 2 | United States | 26 Aug 2021 | |
COVID-19 | Phase 2 | Belgium | 26 Aug 2021 | |
COVID-19 | Phase 2 | Italy | 26 Aug 2021 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
No Data |